Prognostic factors in the treatment of androgenetic alopecia with minoxidil

Introduction. Androgenetic alopecia (AGA) is the most common type of alopecia, characterized by diffuse progressive thinning of the hair in the fronto-parietal area in patients with a genetic predisposition. Topical minoxidil remains the primary pharmacological treatment for AGA both in men and women. The efficacy in hair regrowth is reported to be between 40 and 50%.
Aim. To evaluate prognostic factors of minoxidil response in AGA patients.
Matherials and methods. The prospective open study was carried out. Thirty participants with AGA were enrolled and completed the study (twenty one women I–II Ludwig stage and nine men I–III Hamilton – Norwood stage). Primary outcomes consisted of measuring of hair density, telogen hair rate, the percentage of vellus hairs and hair diameter at baseline and repeated at 4 months. The SULT1A1 enzyme activity and the concentration of ATP in plucked hairs were measured at baseline. Patients were treated with 5% topical minoxidil applying daily for 4 months. In order to investigate prognostic factors in groups of responders and non-responders to minoxidil treatment these measured morphometric and biochemical characteristics were assessed.
Results. After 4 months of treatment 77% of patients demonstrated hair regrowth and improvement of hair density, hair diameter and decrease of vellus hairs level. The SULT1A1 enzyme activity (p = 0.0008), the concentration of ATP (p = 0.004) in plucked hairs and baseline total hair density (p = 0.01) was significantly lower in group of non-responders compared to group of responders. The study demonstrated strong positive correlation between SULT1A1 enzyme activity and increase of total hair density (r = 0.7, р = 0.00002); moderate positive correlation was founded between concentration of ATP and increase of total hair density (r = 0.6, р = 0.0004).
Conclusion. The negative prognostic factors for minoxidil treatment of AGA include SULT1A1 enzyme activity, concentration of ATP in plucked hairs and low total hair density at baseline.

1. Kanti V., Messenger A., Dobos G., Reygagne P., Finner A., Blumeyer A. et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22. https://doi.org/10.1111/jdv.14624.

2. Blumeyer A., Tosti A., Messenger A., Reygagne P., Del Marmol V., Spuls P.I. et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl. 6):S1–57. https://doi.org/10.1111/j.1610-0379.2011.07802.x.

3. Alsantali A., Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes. 2009;16(3):246–253. https://doi.org/10.1097/med.0b013e-32832b100a.

4. Whiting D.A. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993;28(5-1):755–763. https://doi.org/10.1016/0190-9622(93)70106-4.

5. Olsen E.A., Whiting D., Bergfeld W., Miller J., Hordinsky M., Wanser R. et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767–774. https://doi.org/10.1016/j.jaad.2007.04.012.

6. Olsen E.A., Dunlap F.E., Funicella T., Koperski J.A., Swinehart J.M., Tschen E.H., Trancik R.J. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385. https://doi.org/10.1067/mjd.2002.124088.

7. Manabe M., Tsuboi R., Itami S., Osada S.I., Amoh Y., Ito T. et al. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. J Dermatol. 2018;45(9):1031–1043. https://doi.org/10.1111/1346-8138.14470.

8. Olsen E.A., Weiner M.S. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol. 1987;17(1):97–101. https://doi.org/10.1016/s0190-9622(87)70179-0.

9. Blume-Peytavi U., Hillmann K., Dietz E., Canfield D., Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126–1134.e2. https://doi.org/10.1016/j.jaad.2010.09.724.

10. York K., Meah N., Bhoyrul B., Sinclair R. A review of the treatment of male pattern hair loss. Expert Opin Pharmacother. 2020;21(5):603–612. https://doi.org/10.1080/14656566.2020.1721463.

11. Vavilov V.V., Tsimbalenko T.V., Kaverina I.V. Phototrichogram as a tool to assess the effectiveness of minoxidil therapy in patients with androgenetic alopecia. Klinicheskaya Dermatologiya i Venerologiya. 2016;15(6):56–65. (In Russ.) https://doi.org/10.17116/klinderma201615656-65.

12. Anderson R.J., Kudlacek P.E., Clemens D.L. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109(1-3):53–67. https://doi.org/10.1016/s0009-2797(97)00120-8.

13. Buhl A.E., Waldon D.J., Baker C.A., Johnson G.A. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553–557. https://doi.org/10.1111/1523-1747.ep12504905.

14. Roberts J., Desai N., McCoy J., Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014;27(4):252–254. https://doi.org/10.1111/dth.12130.

15. Goren A., Mccoy J., Kovacevic M., Situm M., Chitalia J., Dhurat R. et al. The effect of topical minoxidil treatment on follicular sulfotransferase enzymatic activity. J Biol Regul Homeost Agents. 2018;32(4):937–940. Available at: https://pubmed.ncbi.nlm.nih.gov/30043580/.

16. Sharma A., Goren A., Dhurat R., Agrawal S., Sinclair R., Trüeb R.M. et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019;32(3):e12915. https://doi.org/10.1111/dth.12915.

17. Goren A., Sharma A., Dhurat R., Shapiro J., Sinclair R., Situm M. et al. Lowdose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018;31(6):e12741. https://doi.org/10.1111/dth.12741.

18. Goren A., Shapiro J., Roberts J., McCoy J., Desai N., Zarrab Z. et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatol Ther. 2015;28(1):13–16. https://doi.org/10.1111/dth.12164.

19. Mikhalchik E.V., Smolina N., Ibragimova G.A., Suprun M.V., Fedorkova M.V., Gadzhigoroeva A.G. A set of indicators for assessing the condition of human hair. Moscow: Federal Research and Clinical Center for Physical and Chemical Medicine; 2015. 35 p. (In Russ.)

20. Adachi K., Takayasu S., Takashima I., Takashima I., Kano M., Kondo S. Human hair follicles: metabolism and control mechanisms. J Soc Cosmet Chem. 1970;21:901–924.

21. Mikhal’chik E.V., Suprun M.V., Fedorkova M.V., Ibragimova G.A., Dmitrieva E.I., Lipatova V.A., Kutsev S.I. Evaluation of ATP content in hair bulbs in human scalp. Bulletin of Experimental Biology and Medicine. 2014;157(1):112–115. https://doi.org/10.1007/s10517-014-2504-2.

22. Rogers G.E. Hair follicle differentiation and regulation. Int J Dev Biol. 2004;48(2-3):163–170. https://doi.org/10.1387/ijdb.15272381.

23. Shorter K., Farjo N.P., Picksley S.M., Randall V.A. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725–1736. https://doi.org/10.1096/fj.07-099424.

24. Greig A.V., Linge C., Burnstock G. Purinergic receptors are part of a signalling system for proliferation and differentiation in distinct cell lineages in human anagen hair follicles. Purinergic Signal. 2008;4(4):331–338. https://doi.org/10.1007/s11302-008-9108-0.

25. Cipriani C., Moretti G., Rampini E., Divano C. Adenyl-cyclase activity in rathair-cycle. Arch Dermatol Res (1975). 1976;256(3):319–325. https://doi.org/10.1007/BF00572498.

26. De Villez R.L. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. 1985;121(2):197–202. https://doi.org/10.1001/archderm.121.2.197.